

K983289

JAN 29 1999

Section II

510(k) Summary

510(k) Summary

Submitter's Name/Address

Abbott Laboratories
1920 Hurd Drive
Irving, Texas 75038

Contact Person

Linda Morris
Senior Regulatory Specialist MS 1-8
Regulatory Affairs
(972) 518-6711
Fax (972) 753-3367

Date of Preparation of this Summary:

Month, 1998

Device Trade or Proprietary Name:

ApoA

Device Common/Usual Name or Classification Name:

Apolipoprotein A1

Classification Number/Class:

Class II

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: 698328.9

Test Description:

Apolipoprotein A1 is an *in vitro* diagnostic assay for the quantitative determination of apolipoprotein A1 in human serum or plasma. Antibodies to apolipoprotein A1 combine with apolipoprotein A1 in the sample to form insoluble immune complexes. The immune complexes cause an increase in light scattering (turbidity). The resulting increase in sample turbidity, measured at 804 nm, is directly proportional to the concentration of apolipoprotein A1 in the sample.

Substantial Equivalence:

The Apolipoprotein A1 assay is substantially equivalent to the K-ASSAY® Apo A1 (K964292) on the Hitachi® 717 Analyzer.

Both assays yield similar Performance Characteristics.

Similarities:

- Both assays are *in vitro* immunoassay methods.
- Both assays can be used for the quantitative determination of apolipoprotein A1.
- Both assays yield similar clinical results.
- Both assays are based on the formation of immune complexes.

Differences:

- There is a difference between the assay range.

Intended Use:

The Apolipoprotein A1 assay is used for the quantitation of apolipoprotein A1 in human serum or plasma.

Performance Characteristics:

Comparative performance studies were conducted using the AEROSET™ System. The Apolipoprotein A1 assay method comparison yielded acceptable correlation with the K-ASSAY Apo A1 on the Hitachi 717 Analyzer. The correlation coefficient = 0.9919, slope = 0.976, and Y-intercept = 6.236 mg/dL. Precision studies were conducted using the Apolipoprotein A1 assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 401 is 2.1% and Level 2/Panel 402 is 2.1%. The Apolipoprotein A1 assay range is up to 464 mg/dL. The limit of quantitation (sensitivity) for the Apolipoprotein A1 assay is 0.525 mg/dL. These data demonstrate that the performance of the Apolipoprotein A1 assay is substantially equivalent to the performance of the K-ASSAY Apo A1 on the Hitachi 717 Analyzer.

Conclusion:

The Apolipoprotein A1 assay is substantially equivalent to the K-ASSAY Apo A1 on the Hitachi 717 Analyzer as demonstrated by results obtained in the studies.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JAN 29 1999

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Linda Morris
Senior Regulatory Specialist
Abbott Laboratories
1920 Hurd Drive
Irving, Texas 75038

Re: K983289
Trade Name: AEROSET Apolipoprotein A1
Regulatory Class: II
Product Code: DER
Dated: December 3, 1998
Received: December 4, 1998

Dear Ms. Morris:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D, M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): _____

Device Name: Apolipoprotein A1

Indications For Use:

The Apolipoprotein A1 assay is used for the quantitation of apolipoprotein A1 in human serum or plasma. Measurement of A lipoproteins, the major proteins found in HDL (high density lipoprotein), is used in the diagnosis and treatment of premature coronary artery disease, hyper- α -lipoproteinemia, and hypo- α -lipoproteinemia.

Jean Cooper
K 983289
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number *K 983289*

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use ☒ OR Over-The-Counter Use _____
(Per 21 CFR 801.109)
(Optional Format 1-2-96)